Off-the-shelf cancer vaccines targeting KRAS and other poorly immunogenic oncogenes to prevent and treat common cancers.
Adventris Pharmaceuticals develops off-the-shelf cancer vaccines using a platform that solves the challenge of targeting poorly immunogenic oncogenes. Its first vaccine targets KRAS, the most common cancer oncogene. The long-term vision is annual pan-cancer vaccines for adults that could prevent the majority of cancer deaths. The company is in early-stage development and backed by Y Combinator (Winter 2023). Adventris Pharmaceuticals is a product of Adventris Pharmaceuticals.